Atherosclerosis: From biology to pharmacological treatment

Journal of Geriatric Cardiology

Volumn 9, Issue 3, 2012, Pages 305-317

  Riccioni, Graziano ^a   Sblendorio, Valeriana ^a  

^a NONE

Author keywords

Atherosclerosis; Carotid intima media thickness; Coronary heart disease; Hypertension; Metabolic syndrome; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CXCR2; CLOPIDOGREL; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE MIGRATION INHIBITION FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PRASUGREL; PRAVASTATIN; PROSTACYCLIN; RANTES; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SEROTONIN; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTICOAGULANT THERAPY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; GRANULOMA; HEALTH CARE QUALITY; HUMAN; IMMUNOMODULATION; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SHEAR STRESS; TH2 CELL; THROMBOCYTE ACTIVATION; THROMBOGENICITY;

EID: 84873722293     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1263.2012.02132     Document Type: Review

References (133)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. [PubMed] (Pubitemid 36019640)
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695. [PubMed]
3. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361-366. [PMC free article] [PubMed] (Pubitemid 30313346)
4. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47:7-12. [PubMed]
5. Van Lammeren G, Patterson AJ, Tunnicliffe EM, et al. Atherosclerotic plaque biomarkers: beyond the horizon of the vulnerable plaque. Curr Cardiol Rev. 2011;7:22-27. [PMC free article] [PubMed]
6. Roger VL, Go AS, Lloyd-Jones DM, et al. American heart association statistics committee and stroke statistics subcommittee: heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:18-209. [PubMed]
7. Fuster V, Mearns BM. The CVD paradox-mortality vs prevalence. Nat Rev Cardiol. 2009;6:669. [PubMed]
8. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944. [PubMed]
9. Nordestgaard BG, Adourian AS, Freiberg JJ, et al. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem. 2010;56:559-567. [PubMed]
10. Blankenberg S, Zeller T, Saarela O, et al. MORGAM Project: contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388-2397. [PubMed]
11. Wald NJ, Morris JK. Assessing risk factors as potential screening tests: a simple assessment tool. Arch Intern Med. 2011;171:286-291. [PubMed]
12. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology oundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:50-103. [PubMed]
13. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-176. [PubMed]
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671. [PubMed]
15. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque-part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954. [PubMed] (Pubitemid 41316498)
16. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47:7-12. [PubMed]
17. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-957. [PubMed] (Pubitemid 351305938)
18. Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791. [PubMed] (Pubitemid 23165620)
19. Ambrose JA. In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention? J Am Coll Cardiol. 2008;51:1539-1542. [PubMed] (Pubitemid 351508365)
20. Fuster V, Fayad ZA, Moreno PR, et al. Atherothrombosis and high risk plaque: part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005;46:1209-1218. [PubMed] (Pubitemid 41615539)
21. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57. [PubMed]
22. Saam T, Hatsukami TS, Takaya N, et al. The vulnerable, or high risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology. 2007;244:64-77. [PubMed] (Pubitemid 46981959)
23. Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527-2535. [PubMed]
24. Boekhorst BC, van Tilborg GA, Strijkers GJ, et al. Molecular MRI in inflammation of atherosclerosis. Curr Cardiovasc Imaging Rep. 2012;5:60-68. [PMC free article] [PubMed]
25. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519. [PubMed] (Pubitemid 43980523)
26. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581. [PubMed]
27. Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosc. 2008;13:453-461. [PubMed] (Pubitemid 351599757)
28. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31. [PubMed] (Pubitemid 40171256)
29. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934. [PubMed] (Pubitemid 34627899)
30. Cipollone F, Fazia M, Mincione G, et al. Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke. 2004;35:2253-2257. [PubMed] (Pubitemid 39311245)
31. Braunersreuther V, Zernecke A, Arnaud C, et al. CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373-379. [PubMed] (Pubitemid 46143054)
32. Potteaux S, Combadière C, Esposito B, et al. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:1858-1863. [PubMed] (Pubitemid 44305341)
33. Ionita MG, Vink A, Dijke IE, et al. High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2009;29:1220-1227. [PubMed]
34. Bot I, de Jager SC, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007;115:2516-2525. [PubMed] (Pubitemid 46763225)
35. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008;117:1594-1602. [PubMed] (Pubitemid 351440647)
36. de Kleijn DP, Moll FL, Hellings WE, et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol. 2010;30:612-619. [PubMed]
37. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA. 1991;88:5252-5256. [PMC free article] [PubMed] (Pubitemid 21914722)
38. Rutanen J, Leppänen P, Tuomisto TT, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res. 2003;59:971-979. [PubMed] (Pubitemid 38366253)
39. Roy H, Bhardwaj S, Babu M, et al. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-κB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits. FASEB J. 2006;20:2159-2161. [PubMed]
40. Lucerna M, Zernecke A, de Nooijer R, et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood. 2007;109:122-129. [PubMed] (Pubitemid 46053052)
41. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011;20:51-61. [PubMed]
42. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40. [PubMed] (Pubitemid 46066771)
43. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67. [PubMed] (Pubitemid 36098261)
44. Kraaijeveld AO, de Jager SC, de Jager WJ, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation. 2007;116:1931-1941. [PubMed] (Pubitemid 350287089)
45. Rong JX, Rangaswamy S, Shen L, et al. Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler Thromb Vasc Biol. 1998;18:1885-1894. [PubMed] (Pubitemid 28565750)
46. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714. [PubMed]
47. Naruse K, Shimizu K, Muramatsu M, et al. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium dependent relaxation. Arterioscler Thromb. 1994;14:746-752. [PubMed]
48. Wang BY, Singer AH, Tsao PS, et al. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol. 1994;23:452-458. [PubMed] (Pubitemid 24049378)
49. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954. [PubMed] (Pubitemid 30131694)
50. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906. [PubMed] (Pubitemid 30225269)
51. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658. [PubMed] (Pubitemid 34851922)
52. Shaw JA, Chin-Dusting JP, Kingwell BA, et al. Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease. Circulation. 2001;103:806-812. [PubMed] (Pubitemid 32163877)
53. Schafer A, Alp NJ, Cai S, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol. 2004;24:1720-1726. [PubMed] (Pubitemid 39180901)
54. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. 2005;31:234-246. [PubMed] (Pubitemid 40605197)
55. Hoffmeister HM, Jur M, Ruf-Lehmann M, et al. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol. 1998;31:547-551. [PubMed] (Pubitemid 28144119)
56. Miller DL, Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leuk Biol. 1998;63:373-379. [PubMed] (Pubitemid 28106852)
57. Gertz SD, Roberts WC. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques. Am J Cardiol. 1990;66:1368-1372. [PubMed]
58. Belkhiri A, Richards C, Whaley M, et al. Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest. 1997;77:533-539. [PubMed] (Pubitemid 27508624)
59. Taraboletti G, D'Ascenzo S, Barsotti P, et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol. 2002;160:673-680. [PMC free article] [PubMed] (Pubitemid 34160345)
60. Tricot O, Mallat Z, Heymes C, et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation. 2000;101:2450-2453. [PubMed] (Pubitemid 30366245)
61. Sumi T, Yamashita A, Matsuda S, et al. Disturbed blood flow induces erosive injury to smooth muscle cell rich neointima and promotes thrombus formation in rabbit femoral artery. J Thromb Haemost. 2010;8:1394-1402. [PubMed]
62. Sluimer JC, Daemen MJ. Novel concept in atherogenesis: Angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:7-29. [PubMed]
63. Sluimer JC, Kolodgie FD, Bijnens AP, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions: relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009;53:1517-1527. [PMC free article] [PubMed]
64. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic Plaque Progression and Vulnerability to Rupture Angiogenesis as a Source of Intraplaque Hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061. [PubMed] (Pubitemid 41416300)
65. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein Edeficient mice. Circulation. 1999;99:1726-1732. [PubMed] (Pubitemid 29162486)
66. Jain RK, Finn AV, Kolodgie FD, et al. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med. 2007;4:491-502. [PubMed] (Pubitemid 47316647)
67. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. [PubMed]
68. Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol. 2009;31:79-94. [PubMed]
69. Emerging Risk Factors Collaboration. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140. [PMC free article] [PubMed]
70. Trion A, de Maat MP, Jukema JW, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635-1640. [PubMed] (Pubitemid 41098933)
71. Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis. 2007;195:10-18. [PubMed]
72. Kraaijeveld AO, de Jager SC, van Berkel TJ, et al. Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr Pharm Des. 2007;13:1039-1052. [PubMed] (Pubitemid 46705204)
73. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211-217. [PubMed] (Pubitemid 32128725)
74. Kanse SM, Parahuleva M, Muhl L, et al. Factor VII- activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost. 2008;99:286-289. [PubMed] (Pubitemid 351230957)
75. Naruko T, Furukawa A, Yunoki K, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina. Heart. 2010;96:1716-1722. [PubMed]
76. Verhoeven BA, Velema E, Schoneveld AH, et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Eur J Epidemiol. 2004;19:1127-1133. [PubMed] (Pubitemid 40228502)
77. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002;105:2000-2004. [PubMed] (Pubitemid 34437631)
78. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298. [PubMed] (Pubitemid 20364735)
79. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992;339:563-569. [PubMed]
80. Riccioni G. Statins and carotid intima-media thickness reduction: an up-to-date review. Curr Med Chem. 2009;16:1799-1805. [PubMed]
81. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933. [PubMed] (Pubitemid 32183796)
82. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002;88:41-47. [PubMed] (Pubitemid 34752265)
83. Tuomisto TT, Lumivuori H, Kansanen E, et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res. 2008;78:175-184. [PubMed] (Pubitemid 351430960)
84. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104:387-392. [PubMed] (Pubitemid 32678266)
85. Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45:1946-1953. [PubMed] (Pubitemid 40814113)
86. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol. 2005;96:61-68. [PubMed]
87. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. [PubMed] (Pubitemid 38477774)
88. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278. [PubMed] (Pubitemid 46467240)
89. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. [PubMed] (Pubitemid 32758501)
90. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2005. [PubMed]
91. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. [PubMed]
92. Olsson G, Rehnqvist N, Sjögren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol. 1985;5:1428-1437. [PubMed] (Pubitemid 15069520)
93. Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med. 2007;147:10-18. [PubMed] (Pubitemid 351664629)
94. Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001;38:395-405. [PubMed] (Pubitemid 32769559)
95. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153. [PubMed]
96. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. [PubMed] (Pubitemid 351522739)
97. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol. 2009;20:321-326. [PubMed]
98. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794. [PubMed]
99. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-mediathickness. N Engl J Med. 2009;361:2113-2122. [PubMed]
100. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I (milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103:3047-3050. [PubMed] (Pubitemid 32587849)
101. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455. [PubMed]
102. Jandeleit-Dahm KA, Calkin A, Tikellis C, et al. Direct antiatherosclerotic effects of PPAR agonists. Curr Opin Lipidol. 2009;20:24-29. [PubMed]
103. Meisner F, Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in non-diabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2006;26:845-850. [PubMed] (Pubitemid 43732161)
104. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135. [PubMed]
105. Häkkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917. [PubMed] (Pubitemid 30029817)
106. Wilensky RL, Shi Y, Mohler ER, 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066. [PMC free article] [PubMed]
107. Serruys PW, García-García HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-1182. [PubMed]
108. de Nooijer R, Verkleij CJ, von der Thüsen JH, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340-346. [PubMed] (Pubitemid 43732197)
109. Sukhova GK, Zhang Y, Pan JH, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111:897-906. [PMC free article] [PubMed] (Pubitemid 37074965)
110. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009;15:97-103. [PubMed]
111. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226. [PubMed] (Pubitemid 35373552)
112. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol. 2005;25:18-28. [PubMed] (Pubitemid 40054250)
113. Ludewig B, Freigang S, Jäggi M, et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci USA. 2000;97:12752-12757. [PMC free article] [PubMed]
114. Menges M, Rößner S, Voigtländer C, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 2002;195:15-21. [PMC free article] [PubMed] (Pubitemid 34074492)
115. Maciosek MV, Coffield AB, Flottemesch TJ, et al. Greater use of preventive services in US health care could save lives at little or no cost. Health Aff (Millwood) 2010;29:1656-1660. [PubMed]
116. Wilson JT, Lloyd-Jones DM. Biomarkers for coronary heart disease clinical risk prediction: A critical appraisal. Prev Cardiol. 2010;13:160-165. [PubMed]
117. Katch H, Mead H. The role of self-efficacy in cardiovascular disease self-management: a review of effective programs. Patient Intelligence. 2010;2:33-44.
118. Bosworth HB. Challenges and strategies to improve patient health literacy and competencies. Patient Intelligence. 2010;2:19-25.
119. McNeal TM, Colbert CY, Cable C, et al. Patients' attention to and understanding of adverse drug reaction warnings. Patient Intelligence. 2010;2:59-68.
120. Webster R, Heeley E. Perceptions of risk: understanding cardiovascular disease. Risk Manag Healthc Policy. 2010;3:49-60. [PMC free article] [PubMed]
121. Mosca L, Mochari-Greenberger H, Dolor RJ, et al. Twelve- year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3:120-127. [PMC free article] [PubMed]
122. Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998;279:1288-1292. [PubMed] (Pubitemid 28180782)
123. Ritchie JE, Herscovitch F, Norfor JB. Beliefs of blue collar workers regarding coronary risk behaviours. Health Educ Res. 1994;9:95-103. (Pubitemid 24075534)
124. Norcross JC, Krebs PM, Prochaska JO. Stages of change. J Clin Psychol. 2011;67:143-154. [PubMed]
125. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11:1-47. [PubMed]
126. Weinstein ND. Unrealistic optimism about susceptibility to health problems: conclusions from a community-wide sample. J Behav Med. 1987;10:481-500. [PubMed] (Pubitemid 18019030)
127. De Koning JS, Klazinga NS, Koudstaal PJ, et al. Quality of care in stroke prevention: results of an audit study among general practitioners. Prev Med. 2004;38:129-136. [PubMed] (Pubitemid 38050284)
128. De Muylder R, Lorant V, Paulus D, et al. Obstacles to cardiovascular prevention in general practice. Acta Cardiol. 2004;59:119-125. [PubMed] (Pubitemid 38506579)
129. Eaton CB, Galliher JM, McBride PE, et al. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med. 2006;19:46-53. [PubMed] (Pubitemid 44046993)
130. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2006;13:839-845. [PubMed] (Pubitemid 44454860)
131. Kones R. Rosuvastatin, inflammation, C-reactive Protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther. 2010;4:383-413. [PMC free article] [PubMed]
132. Rubin J, Chang H-J, Nasir K, et al. Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. Circ Cardiovasc Imaging. 2011;4:201-209. [PubMed]
133. Riccioni G. Integrated control of hypertension, dyslipidemia and carotid atherosclerosis in the reduction of cardiovascular risk. Exp Rev Card Ther. 2007;5:371-374. [PubMed] (Pubitemid 46805569)